Some of the results to date have been remarkable, including the near-normalization of life expectancy for chronic myelogenous leukemia—a previously fatal disease—when the molecular BCR-ABL aberration is targeted by cognate inhibitors early in the disease [36]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.